Histologic and immunohistochemical decision-making in endometrial adenocarcinoma

Modern Pathology

Volumn 21, Issue 8, 2008, Pages 937-942

  Lomo, Lesley ^a   Nucci, Marisa R ^a   Lee, Kenneth R ^a   Lin, Ming Chieh ^b   Hirsch, Michelle S ^a   Crum, Christopher P ^a   Mutter, George L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Endometrial neoplasms; p53; Reproducibility; Serous carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; DECISION MAKING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPPA STATISTICS; MAJOR CLINICAL STUDY; PATHOLOGIST; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

BIOPSY; CYSTADENOCARCINOMA, SEROUS; DECISION MAKING; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48749085124     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.97     Document Type: Article

References (16)

1. Deligdisch L, Holinka C. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-246.
2. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
3. Hendrikson M, Ross J, Eifel P, et al. Uterine papillary serous adenocarcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
4. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
5. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24:797-806.
6. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-1578.
7. Boruta II DM, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004;101:2214-2221.
8. Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004;12:207-223.
9. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-1267.
10. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23:129-137.
11. Osmanagaoglu MA, Kadioglu S, Osmanagaoglu S, et al. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma. Eur J Gynaecol Oncol 2005;26:64-70.
12. Ozalp S, Yalcin OT, Tanir HM, et al. p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 2003;24:275-278.
13. Coronado PJ, Vidart JA, Lopez-asenjo JA, et al. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001;98:103-108.
14. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 2003;88:318-325.
15. Lundgren C, Auer G, Frankendal B, et al. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2004;43:49-56.
16. Bonfitto VL, de Angelo Andrade LA. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy. Sao Paulo Med J 2003;121:163-166.